These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7201820)

  • 41. Assessing African medicinal plants for efficacy and safety: pharmacological screening and toxicology.
    Fennell CW; Lindsey KL; McGaw LJ; Sparg SG; Stafford GI; Elgorashi EE; Grace OM; van Staden J
    J Ethnopharmacol; 2004 Oct; 94(2-3):205-17. PubMed ID: 15325724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Preclinical toxicology of bisphosphonates].
    Mondelo N; Peluffo VA; Parma MD; Cointry GR; Capozza RF; Ferretti JL; Piccinni E; Montuori E
    Medicina (B Aires); 1997; 57 Suppl 1():93-100. PubMed ID: 9567361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.
    Hegen M; Keith JC; Collins M; Nickerson-Nutter CL
    Ann Rheum Dis; 2008 Nov; 67(11):1505-15. PubMed ID: 18055474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statistical considerations in clinical field evaluation of drugs.
    Powers JD; Powers TE
    J Am Vet Med Assoc; 1980 May; 176(10 Spec No):1151-2. PubMed ID: 7216891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [General schema for safety evaluation of residues of embryotoxic drugs (author's transl)].
    Delatour P; Boisseau J; Burgat V; Mergier P; Milhaud G; Richou-Bac L; Rico A; Siou G
    Ann Rech Vet; 1981; 12(2):215-8. PubMed ID: 7342838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Preclinical safety tests of new drugs using laboratory rats in terms of medullary haematopoietic inhibition (author's transl)].
    Berger J
    Cas Lek Cesk; 1981 Aug; 120(33):987-90. PubMed ID: 7296622
    [No Abstract]   [Full Text] [Related]  

  • 47. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
    Hondeghem LM
    Eur J Pharmacol; 2008 Apr; 584(1):1-9. PubMed ID: 18304526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Embracing complexity in drug discovery.
    Gund P; Maliski E; Brown F
    Curr Opin Drug Discov Devel; 2007 May; 10(3):252-3. PubMed ID: 17554850
    [No Abstract]   [Full Text] [Related]  

  • 49. [Investigation of bone marrow in preclinical safety tests of new drugs (author's transl)].
    Berger J
    Cas Lek Cesk; 1982 Jan; 121(4):97-101. PubMed ID: 7060066
    [No Abstract]   [Full Text] [Related]  

  • 50. In silico methods for early toxicity assessment.
    Merlot C
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Control, drug preparation and dosage in the designing of experiments (author's transl)].
    Chen X
    Zhonghua Yi Xue Za Zhi; 1981 Jun; 61(6):335-8. PubMed ID: 6796231
    [No Abstract]   [Full Text] [Related]  

  • 52. Small molecule immunomodulatory drugs: challenges and approaches for balancing efficacy with toxicity.
    Haley PJ
    Toxicol Pathol; 2012; 40(2):261-6. PubMed ID: 22083586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of hematologic parameters in applying the principles of toxicity testing to biotechnology products.
    Payne BJ
    Prog Clin Biol Res; 1987; 235():107-20. PubMed ID: 3601999
    [No Abstract]   [Full Text] [Related]  

  • 54. [General principles of clinical therapeutic trials].
    Sancho H
    Acta Chir Belg; 1976 Jan; 75(1):19-29. PubMed ID: 790880
    [No Abstract]   [Full Text] [Related]  

  • 55. [Organization of the work of the Republican Center for Preclinical Study of New Drugs].
    Sokolova GB; Kunichan AD; Shubin AI
    Probl Tuberk; 1991; (9):27-9. PubMed ID: 1836264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A behavioural test applied in an acute toxicity screen [proceedings].
    Silverman AP
    Br J Pharmacol; 1978 Jun; 63(2):349P-350P. PubMed ID: 667432
    [No Abstract]   [Full Text] [Related]  

  • 57. Logistics of therapeutic trials: the example of cancerology.
    Mathé G; Kenis Y
    Biomedicine; 1973 May; 18(3):181-4. PubMed ID: 4742859
    [No Abstract]   [Full Text] [Related]  

  • 58. Chick embryotoxicity screening test--130 substances tested.
    Jelinek R; Peterka M; Rychter Z
    Indian J Exp Biol; 1985 Oct; 23(10):588-95. PubMed ID: 3833676
    [No Abstract]   [Full Text] [Related]  

  • 59. [Screening methods of chemical mutagen by Paramecium tetraurelia (author's transl)].
    Fukushima S; Ogawa H; Shiota C; Sasagawa S
    Nihon Eiseigaku Zasshi; 1979 Dec; 34(5):664-9. PubMed ID: 544844
    [No Abstract]   [Full Text] [Related]  

  • 60. [MASCA-model of the biochemical-pharmacological drug research/ part 4: Structure-activity relationships and MANOVA (author's transl)].
    Mager PP
    Arzneimittelforschung; 1975 Oct; 25(10):1475-6. PubMed ID: 1243023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.